Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

BCEL - Atreca Inc - Class A


Close
0.15
-0.020   -13.333%

Share volume: 655,684
Last Updated: Mon 18 Mar 2024 09:00:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$0.17
-0.02
-11.77%
This ticker is disabled and data are no longer maintained and up to date.
Fundamental analysis
12%
Profitability 18%
Dept financing 4%
Liquidity 50%
Performance 0%
Company vs Stock growth
vs
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$0.15
P/E Ratio 
0.00
DAY RANGE
$0.15 - $0.19
EPS 
$0.00
52 WEEK RANGE
$0.00 - $0.00
52 WEEK CHANGE
$0.00
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
32.909 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$0
AVERAGE 30 VOLUME 
$0
Company detail
CEO: John Orwin
Region: US
Website: http://www.atreca.com/
Employees: 101
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

atreca is a biotechnology company that develops novel therapeutics through a deep understanding of the human immune response, with a focus on innovative novel cancer immunotherapeutics. with its immune repertoire capture™ (irc™) technology, atreca has an unparalleled insight into how cancer patients’ immune responses can drive better clinical outcomes. atreca was founded by scientists, industry experts, and investors who share the vision that unlocking the immune response of today’s patients is the key to creating a new generation of therapies. atreca is looking for talented, entrepreneurial people who are dedicated to making a positive impact on human health. if you are interested in becoming part of the atreca team, our open positions can be found at: http://www.atreca.com/careers/

Recent news